Know before
symptoms start.
OncuraKit screens for 6 cancer types from a single urine sample — using Nobel Prize-winning microRNA science with >97% sensitivity.
No blood draw. No appointment. No waiting room.
Built for everyone who believes
early detection matters.
Whether you're an individual taking charge of your health, a company protecting your team, or a healthcare organization expanding access — OncuraKit meets you where you are.
Take control before symptoms appear.
For adults who want answers — not a waiting room.
- 1 in 100 adults over 60 are likely to develop cancer
- Stage I survival rate exceeds 90% for most cancer types
- No prescription, no appointment, no needles
Protect your team. Reduce catastrophic costs.
Add OncuraKit to your employee benefits package.
- Late-stage cancer treatment averages $150,000–$800,000
- Early detection reduces employer health plan spend by 60%+
- Bulk pricing and HR reporting available for companies of any size
Offer patients the most sensitive MCED test available.
Integrate OncuraKit into your patient care pathway.
- 81–97% Stage I/II sensitivity — highest published among all MCEDs
- Urine-only: ideal for patients who can't tolerate blood draws
- CLIA-certified Yenos report with physician interpretation guide
Early detection
changes everything.
When cancer is caught at Stage I or II, most types are highly treatable. By Stage IV, many become nearly impossible to survive. The window between those two realities is where OncuraKit operates.
5-Year Survival Rate: Stage I vs. Stage IV
Source: American Cancer Society, National Cancer Institute
OncuraKit detects microRNA threats before symptoms appear
Colorectal
Pancreatic
Ovarian
Lung
Out of 10 patients diagnosed — who survives?
Colorectal
Pancreatic
Ovarian
Lung
annual cancer deaths occur in cancers with no recommended screening protocol
Americans have postponed health checkups or screenings that could save their lives
detection gives patients the greatest chance of curative treatment and full recovery
Order. Collect. Ship. Done.
From your couch to our California lab — no blood draw, no appointment, no waiting room. Just the clarity you need, in five easy steps.
Order online
2 minutesVisit Oncura.health, complete a simple checkout — no prescription, no appointment. Your kit ships that day.
Kit arrives
2–3 daysYour OncuraKit ships in discreet plain packaging directly to your home with everything you need, including a pre-paid return label.
Collect at home
5 minutesUse the included collection cup to provide a simple urine sample. No blood draw. No needles. No clinic. No awkward appointments.
Ship to our lab
Pre-paid overnightSeal your sample in the included bio-safe mailer and drop it in any USPS or FedEx box. Pre-paid overnight shipping to Yenos Analytical in El Dorado Hills, CA.
Get your results
5–7 daysReceive a secure, detailed digital report in your private dashboard — a clear result for each of the 6 cancer types screened.
Processed at Yenos Analytical — CLIA-Certified
Your sample travels via pre-paid overnight shipping to Yenos Analytical LLC in El Dorado Hills, California. Founded by Dr. Anastassia Kanavarioti (UC Santa Cruz), the CLIA-certified lab uses the MinION/Yenos nanopore platform to analyze your specimen — the same technology behind 4 published peer-reviewed studies. Results are ready in 5–7 days.
The kind of thing you text
someone you actually care about.
Early detection is a conversation. Be the one who starts it.
Mom
iMessage
How detection actually works
The Yenos MinION/Yenos platform measures three validated miRNA cancer biomarkers — miR-21, miR-375, and miR-141 — in a single urine sample. Every healthy person shares the same baseline (1.0 HL). Cancer shifts that to 1.83 HL, with zero overlap between populations.
Biomarker Signal Threshold
Cancer samples express miR-21, miR-375 & miR-141 at 1.83× the healthy level. Threshold is 1.5×. Zero data overlap confirmed (p=1.6×10⁻²²)
Cell-Level miRNA Dysregulation
MicroRNA dysregulation drives abnormal cell growth, differentiation, and apoptosis — the biological basis for all six cancer types detected.
MinION/Yenos Nanopore Platform
2048-nanopore array with 180 pA baseline current. Osmium-tagged probes bind target miRNA; each molecule blocks ion flow — single-molecule detection, amplification-free.
Published Per-Marker Accuracy
Three validated cancer miRNAs: miR-21 (93.8%), miR-375 (81.5%), miR-141 (97.3%). miR-15b serves as internal control (not a cancer marker).
Source: Rafiq & Kanavarioti, Int. J. Mol. Sci. 2025, 26, 3822 · doi:10.3390/ijms26083822
Visualizations are illustrative representations of published analytical methods from Yenos Analytical LLC. Data sourced from Rafiq & Kanavarioti (2025), Kanavarioti et al. (2024, 2022, 2020). Actual lab instrumentation and numerical outputs may vary. OncuraKit is a Laboratory Developed Test (LDT) analyzed by Yenos Analytical, a CLIA-certified laboratory.
No other MCED test
matches this.
Every competing multi-cancer early detection (MCED) test requires blood. Most rely on probabilistic scoring that produces data overlap between cancer and healthy patients. OncuraKit is the only test that delivers a clear YES or NO result from a urine sample, with the highest published Stage I/II sensitivity.
Galleri
Grail Corp
Shield MCD
Guardant Health
CancerGuard
Exact Sciences
Yenos / OncuraKit
Yenos Analytical
Competitor data sourced from Yenos Analytical LLC presentation, January 2026, citing publicly available company pricing and published clinical validation studies. Galleri (Grail Corp), Shield MCD (Guardant Health), CancerGuard (Exact Sciences/Abbott). Prices and performance metrics subject to change.
What success looks like
at every outcome.
No matter what your result is, you'll have a clear path forward — and you won't face it alone.
Outcome A
Normal Result
All markers below 1.5× HL threshold · No overexpression detected
Clear result — within normal range
All three markers are below the 1.5× healthy level threshold. Your body is expressing miR-21, miR-375, and miR-141 in the expected range.
Documented health baseline
Your results are stored securely in your OncuraKit dashboard — a timestamped baseline for annual comparison and peace of mind.
Annual re-screening recommended
We recommend annual screening starting at 60+, or sooner if you receive an inconclusive mammogram, PSA test, or colonoscopy.
Outcome B
Elevated Result
Above 1.5× HL threshold · Second confirmatory test recommended
Receive your detailed report
Your Yenos lab report shows exact HL scores for each of the three miRNA markers, with a clear Elevated or Normal classification for each.
We connect you with a clinician
OncuraKit provides a complimentary physician consultation to walk through your results and recommend appropriate next steps.
Your doctor guides follow-up testing
A positive screen is not a diagnosis. It means a target-specific clinical evaluation is warranted. Most follow-up tests are covered by insurance.
What we believe
OncuraKit exists because we believe early cancer detection shouldn't require a specialist referral, a hospital visit, or even a blood draw. It should be as simple as mailing a letter.
We believe prevention is healthcare
Most cancers detected late are survivable when caught early. We built OncuraKit to shift the conversation from treatment to prevention — putting a powerful screening tool directly in your hands.
We believe science should be accessible
Nobel Prize-winning microRNA research has existed for decades. OncuraKit brings that science out of academic journals and into your home — as a simple, at-home urine test with no clinic visit required.
We believe our test can save lives
While no test can guarantee outcomes, we firmly believe that OncuraKit's >97% sensitivity and specificity — validated in Stage I/II cancer patients — provides the kind of early signal that changes treatment trajectories and saves lives.
We believe the time to test is now
Cancer does not wait for symptoms to appear. By the time most cancers are felt or seen, they are already at an advanced stage. Proactive, annual screening is the only way to stay ahead of it.
Who it's for
From individuals seeking peace of mind to healthcare organizations expanding access.
Who should not take this test
These conditions can affect miRNA expression levels and may produce misleading results. If you are pregnant, in active cancer treatment, or on hormonal therapy, please consult your physician before ordering.
